Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst
In a report released yesterday, Charles Duncan from Cantor Fitzgerald maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), with a price target of $132.00. The company’s shares closed yesterday at $131.87.
Don't Miss Our End of Quarter Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter.
According to TipRanks, Duncan is a top 100 analyst with an average return of 24.9% and a 50.74% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, ACADIA Pharmaceuticals, and Alkermes.
Currently, the analyst consensus on Intra-Cellular Therapies is a Moderate Buy with an average price target of $130.83.
The company has a one-year high of $131.98 and a one-year low of $64.09. Currently, Intra-Cellular Therapies has an average volume of 3.49M.
Read More on ITCI:
Disclaimer & DisclosureReport an Issue
- Intra-Cellular Therapies Reports Strong 2024 Growth
- Alibaba upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Intra-Cellular downgraded to Neutral from Outperform at Mizuho
- Is ITCI a Buy, Before Earnings?
- Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects